Retrospective Review of 374 Samples, Circulating DNA; as a Biomarker Assay to Support Clinical Management in Solid Tumors Treated With Multi Targeted Epigenetic Therapy (MTET)

Here in this abstract we retrospectively review preliminary findings on 374 samples of circulating DNAextracted from 173 patients treated by multitargeted epigenetic therapy (MTET), which is a combination of natural histone deacetylase inhibitors and DNMT methyl transferase inhibitors. This therapy could dynamically interrupt the expression of altered genes, in a variety of solid tumor types, both in invitro and invivo models. We hypothesize that serial monitoring of the circulating DNA provides a feasible option for therapeutic decisions making based on presence of the driver genes in these cases. We also were able to track the antineoplastic response in these group of patients by monitoring their tumor circulating DNA mutated allele fractions and propose a direct correlation with interim epigenetic therapy effectiveness.